Clinical research

SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetes

Phase 3, randomised, active-controlled, in type 2 diabetes. 1,879 randomised, over 40 weeks. Sponsor: Eli Lilly and Company.

SURPASS-2 (NCT03987919) tested at 5, 10 or 15 mg against semaglutide 1 mg in .HbA1c reduction of 2.01% to 2.30% with tirzepatide versus 1.86% with semaglutide 1 mg Unverified — no source on file: the source is a citable record we could not authoritatively link, which we have not independently re-extracted from the full paper in this session.

Study design

Results

HbA1c reduction of 2.01% to 2.30% with tirzepatide versus 1.86% with semaglutide 1 mg

Adverse events & discontinuations

Not extracted from the source in this session.

Limitations

Compares against semaglutide 1 mg, which is below the 2.4 mg dose used for weight management. A glycaemic trial in diabetes; do not read it as a weight-loss comparison.

Practical interpretation

This is one trial, reported by Eli Lilly and Company, read directly against the registry and publication linked below — GLP Ranked has not re-run the statistics or obtained the patient-level data. Results describe group averages under trial conditions and may not describe any individual's outcome, including with a compounded, non-FDA-approved version of a similar active ingredient. Always check the primary source before citing a specific number.